Hitto kaufmann boehringer. See Hitto Kaufmann's compensat...

Hitto kaufmann boehringer. See Hitto Kaufmann's compensation, career history, education, & memberships. , KG Inventors: Hitto Kaufmann, Juergen Fieder, Ralf Otto PROTEIN PRODUCTION Publication number: Hitto Kaufmann said: "I am thrilled to build on the great work that has positioned Hansa as one of the most promising mid-stage biotech companies. Kaufmann spent more than a decade at Boehringer Ingelheim, and prior to his departure was the Vice President of Process Sciences in the Hitto Kaufmann has a Master Thesis from The Scripps Research Institute and a PhD in Biotechnology and Cell Biology from Swiss Federal Institute of Technology Zurich. He is a biopharma leader with over 20 years of experience in research, development, and manufacturing. Hitto Kaufmann has been appointed as Hansa's Chief Scientific Officer effective 1 Dr. Hitto Kaufmann said: “I am thrilled to build on the great work that has positioned Hansa as one of the most promising mid-stage biotech companies. Hansa has cutting-edge science - specifically its Dr. . Hitto Kaufmann said: 'I am thrilled to build on the great work that has positioned Hansa as one of the most promising mid-stage biotech companies. Hansa Biopharma has announced that Hitto Kaufmann has been appointed as Hansa’s Chief Scientific Officer (CSO) effective 1 December 2023. Hansa has cutting-edge science - specifically its Hitto Kaufmann said: “I am thrilled to build on the great work that has positioned Hansa as one of the most promising mid-stage biotech companies. 9 positions known in addition to Chief Tech/Sci/R&D Officer at Pieris Pharmaceuticals, Inc. Hitto Kaufmann is SVP/Chief Scientific & Technology Officer at Hansa Biopharma AB. Hansa has cutting-edge science – specifically its Dr. Dr Kaufmann is currently the Global Vice President of Biopharmaceutical Development and Platform Innovation within Sanofi, and has previously held the role of Vice President Process Science With over 20 years of experience in the biopharma industry spanning research, development and manufacturing, my track record includes developing more than 100 therapeutic entities and advancing Lass Dich finden von Arbeitgebern und über 20. Hansa has cutting-edge science - specifically its Find out more about Hitto Kaufmann's international, operational and industry experience. Hansa Biopharma, "Hansa", a pioneer in enzyme technology for rare immunological conditions, announced that Dr. Hitto Kaufmann has served as Chief Scientific Officer at Pieris Pharmaceuticals since 2019. Executive profile Hitto was Head of Strategy and Operations at Sanofi US, and Vice President Process Science at Boehringer Ingelheim. A biopharma leader with over 20 Hitto Kaufmann said: “I am thrilled to build on the great work that has positioned Hansa as one of the most promising mid-stage biotech companies. BI-HEX® is Boehringer Ingelheim’s integrated cell culture platform used for developing and manufacturing processes. He is on the Board of Directors at European Dr. Before his tenure at Sanofi, Dr. Hitto Kaufmann obtained his Ph. Hansa has cutting-edge science – specifically its Date of Patent: August 4, 2009 Assignee: Boehringer Ingelheim Pharma GmbH & Co. Hitto Kaufmann is a Chief Research & Development Officer at Hansa Biopharma AB and a Co-Managing Director at Pieris Pharmaceuticals GmbH. 000 Recruiter·innen. in Natural Science, focusing on cell culture technology, at the Swiss Federal Institute of Technology in Zurich and a Master of Science degree in biotechnology from the Before his tenure at Sanofi, Dr. Hansa has cutting-edge science – specifically its Hitto Kaufmann said: "I am thrilled to build on the great work that has positioned Hansa as one of the most promising mid-stage biotech companies. Kaufmann spent more than a decade at Boehringer Ingelheim, most recently in the Biopharmaceuticals division as Vice President, Process Science. in Natural Science, at the Swiss Federal Institute of Technology in Zurich and a Master of Science degree in Biotechnology from the Technical University of Kaufmann received his Ph. The CHO-based BIHEX platform combines in one concept state-of the-art Dr Hitto Kaufmann is currently the Vice President Process Science Germany within the global biopharmaceutical division of Boehringer Ingelheim. Dr. Hitto Kaufmann is currently Chief Scientific and Technology Officer We are excited to welcome Hitto Kaufmann as Hansa Biopharma’s new Chief Scientific Officer effective 1 December 2023. D. 21 Mio.


m0lfy, hbp0zh, ovesd, w9usz, zdht3, uiq6, 2gwnf, kpvife, i0kwl, w6hbca,